Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and r

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consen

Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; cli

Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics b

Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ:IFRX) from Outperform to Strong Buy

HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and rai

Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and r

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal D

InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the

Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biop

All ordinary shares in the offering are being sold by the Company. The offering is expected to close

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of es

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a bioph

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical co

JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical com

JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical com

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by

JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by

JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical

InflaRx N.V. (NASDAQ: IFRX - Get Free Report) has been assigned a consensus recommendation of "Moder

InflaRx (NASDAQ: IFRX - Get Free Report) and Athira Pharma (NASDAQ: ATHA - Get Free Report) are both

Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price t

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Est

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.17) per share which beat the analyst consensu

Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differe

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics b

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by

InflaRx outlines restructuring plans, workforce cuts, and reduced Gohibic spending to extend cash ru

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare

HC Wainwright & Co. analyst Matthew Keller reiterates InflaRx (NASDAQ:IFRX) with a Buy and ma

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlie

Leerink Partners analyst Joseph Schwartz downgrades InflaRx (NASDAQ:IFRX) from Outperform to Mark